CorFlow Secures $44 Million in Series B Funding to Revolutionize Cardiac Care with Microvascular Solutions

CorFlow, a pioneering company founded on the principle of enhancing PCI and cardiac care through advanced microvascular diagnostics, has successfully raised an impressive $44 million in its latest funding round. This investment marks a significant step forward for the company, headquartered in Baar, Switzerland, as it endeavors to lead the charge in diagnosing microvascular obstruction (MVO) in real-time during percutaneous coronary interventions (PCI). With its innovative diagnostic and treatment platform currently under clinical investigation, CorFlow is poised to transform clinical outcomes in cardiology and beyond by addressing the crucial yet often overlooked dysfunctions of the microvascular system. The funding will primarily support ongoing clinical studies aimed at validating the safety and efficacy of CorFlow’s groundbreaking technology. Founded in 2016, the company has already garnered support through angel investment, venture capital, and partnerships with the Swiss government to develop cutting-edge healthcare solutions. With Paul Mead at the helm, leveraging nearly two decades of experience at Medtronic, and under the guidance of Rick Geoffrion, CEO of Cyrano Therapeutics, CorFlow is not only focused on immediate advancements in microvascular care but is also committed to a broader mission of improving human life and achieving ambitious environmental, social, and governance targets. This latest funding round sets the stage for CorFlow to further innovate and solidify its vision of becoming a leader in therapeutic solutions for restoring healthy blood flow, ensuring that healthcare providers have the necessary tools to tackle critical challenges in cardiology effectively.